Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
In the SURPASS clinical trial program, tirzepatide reduced A1c by 1.9% to 2.4% from baseline at the highest doses over 40 weeks compared to 1.4% with semaglutide 1 mg in SURPASS-2
Talel Badri
In the short term, patients who were not currently surgical candidates due to high BMI are becoming eligible candidates due to their weight loss
Small amounts of L-carnitine have been given to infants in breast milk and formula with no reported side effects
These emerging options will further increase competition and drive down prices across the entire market
US$ 22.55
US$ 24.61
US$ 24.36
US$ 21.14
US$ 22.34
US$ 23.21
